Skip to main content

Digestive Health and Surgery

Digestive Health and Surgery

Overview

The AdventHealth Digestive Health and Surgery Institute is at the forefront of advanced care for complex diseases in Central Florida — and we’re raising the bar for the industry globally, too. From being home to the largest interventional endoscopy center in the U.S. to holding multiple accreditations for our subspecialty programs, we bring world-class care close to home. Our well-connected, multi-specialty care team has made our institute a destination for digestive and surgical care, and we’re ready to help you feel whole.

The Digestive Health and Surgery Institute is recognized as a Center of Excellence by the National Accreditation Program for Rectal Cancer (NAPRC). And AdventHealth Orlando is recognized by U.S. News & World Report as one of America’s best hospitals for gastroenterology, gastrointestinal surgery and colon cancer surgery.

Contact Information

Digestive Health and Surgery Institute
Robin Barron, DHSI Research Supervisor

Areas of Focus

  • Bariatrics
  • Colorectal Surgery
  • Ear, nose, and Throat
  • Fatty Liver Disease
  • Gastroenterology
  • General Surgery
  • Inflammatory Bowel Disease (IBD)
  • Ophthalmology
  • Plastic Reconstructive Surgery
  • Urology

Featured Clinical Trials

NCT02914561

Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease

Icon for trial | GS-US-419-3895 Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease

This study is currently enrolling.

You have been asked to be part of this study because you have been diagnosed with Crohn’s disease, which is an inflammatory disease of the gastrointestinal tract (digestive tract). The purpose of this study is to see if filgot ...

NCT03466411

A Phase 3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Subject with Moderately to Severely Active Crohn’s Disease

Icon for trial | CNTO1959CRD3001 A Phase 3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Subject with Moderately to Severely Active Crohn’s Disease

This study is currently enrolling.

There are 3 separate studies being described in this form. All 3 studies have the same primary purposes, but there are some small differences between GALAXI 1 (which is a Phase 2 study) and GALAXI 2 & 3 (which are identical ...

Meet the Team

Our Capabilities

The Inflammatory Bowel Disease (IBD) program at CIE was established in 2015 and is a center of excellence devoted to the management of patients with complex ulcerative colitis and Crohn’s disease. More than 500 patients with complex inflammatory bowel disease have been evaluated and undergone treatment through our IBD program.

The IBD program is comprised of a multidisciplinary team which includes a gastroenterologist (with specialized expertise in IBD), colorectal surgeons, nutritionists, radiologists, pathologists and pain management specialists who jointly deliver comprehensive care. A specific emphasis of our program is the management of IBD complications including strictures, fistulas, leaks and early-stage tumors by providing tertiary-level endoscopic treatment. Additionally, colon cancer surveillance is performed utilizing advanced technology such as chromoendoscopy for detection and resection of early-stage tumors.